Success Metrics

Clinical Success Rate
50.0%

Based on 2 completed trials

Completion Rate
50%(2/4)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
2(50%)

Phase Distribution

Ph phase_1
4
100%

Phase Distribution

4

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
4(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

50.0%

2 of 4 finished

Non-Completion Rate

50.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(2)
Terminated(2)

Detailed Status

Terminated2
Completed2

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
50.0%
Most Advanced
Phase 1

Trials by Phase

Phase 14 (100.0%)

Trials by Status

terminated250%
completed250%

Recent Activity

0 active trials
Showing 4 of 4
terminatedphase_1

Safety and Efficacy of AsiDNATM, a DNA Repair Inhibitor, Administered Intravenously in Addition to PARP Inhibitors in Patients With Relapsed Platinum Sensitive Ovarian Cancer Already Treated With PARP Inhibitors Since at Least 6 Months

NCT04826198
completedphase_1

Study to Assess Safety and Efficacy of AsiDNA in Combination with Olaparib in Participants with Recurrent Solid Tumors

NCT05700669
terminatedphase_1

AsiDNA Children, Adolescents and Young Adults

NCT05394558
completedphase_1

AsiDNA (a DNA Repair Inhibitor) Administered IntraVenously in Advanced Solid Tumors

NCT03579628

Clinical Trials (4)

Showing 4 of 4 trials
NCT04826198Phase 1

Safety and Efficacy of AsiDNATM, a DNA Repair Inhibitor, Administered Intravenously in Addition to PARP Inhibitors in Patients With Relapsed Platinum Sensitive Ovarian Cancer Already Treated With PARP Inhibitors Since at Least 6 Months

Terminated
NCT05700669Phase 1

Study to Assess Safety and Efficacy of AsiDNA in Combination with Olaparib in Participants with Recurrent Solid Tumors

Completed
NCT05394558Phase 1

AsiDNA Children, Adolescents and Young Adults

Terminated
NCT03579628Phase 1

AsiDNA (a DNA Repair Inhibitor) Administered IntraVenously in Advanced Solid Tumors

Completed

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4